Alex Chen, Ph.D. · Original report: September 11, 2026 · Web edition: November 7, 2026
Read the full report
The full report contains nine sections, 21 comparison/data tables, 13 evidence callouts and 23 references. A chapter directory lets you go straight to the relevant analysis. You can share a chapter link, download the complete reading page for offline use, or print it to PDF.
The two-minute overview
- A label identifies excipients but does not disclose the complete quantitative formulation or commercial manufacturing process.
- Human enlicitide bioavailability and animal icotrokinra data must be interpreted separately.
- The report keeps sourced facts, development hypotheses and undisclosed information distinct.
Choose a section
Enlicitide: salt selection, composition and absorption
Icotrokinra: formulation, permeability and pharmacokinetics
Development implications and evaluation questions
Scope
This is a public-source, AI-assisted technical analysis of two product-development cases, not a complete oral-peptide market landscape. The underlying report is dated September 11, 2026; its source dates and evidence limitations remain visible. Consult current original sources for subsequent changes.